Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS Pathog ; 14(4): e1006983, 2018 04.
Article in English | MEDLINE | ID: mdl-29614111

ABSTRACT

[This corrects the article DOI: 10.1371/journal.ppat.1006906.].

2.
PLoS Pathog ; 14(3): e1006906, 2018 03.
Article in English | MEDLINE | ID: mdl-29518153

ABSTRACT

HIV-1 arose as the result of spillover of simian immunodeficiency viruses (SIVs) from great apes in Africa, namely from chimpanzees and gorillas. Chimpanzees and gorillas were, themselves, infected with SIV after virus spillover from African monkeys. During spillover events, SIV is thought to require adaptation to the new host species. The host barriers that drive viral adaptation have predominantly been attributed to restriction factors, rather than cofactors (host proteins exploited to promote viral replication). Here, we consider the role of one cofactor, RanBP2, in providing a barrier that drove viral genome evolution during SIV spillover events. RanBP2 (also known as Nup358) is a component of the nuclear pore complex known to facilitate nuclear entry of HIV-1. Our data suggest that transmission of SIV from monkeys to chimpanzees, and then from chimpanzees to gorillas, both coincided with changes in the viral capsid that allowed interaction with RanBP2 of the new host species. However, human RanBP2 subsequently provided no barrier to the zoonotic transmission of SIV from chimpanzees or gorillas, indicating that chimpanzee- and gorilla-adapted SIVs are pre-adapted to humans in this regard. Our observations are in agreement with RanBP2 driving virus evolution during cross-species transmissions of SIV, particularly in the transmissions to and between great ape species.


Subject(s)
Biological Evolution , HIV Infections/virology , Molecular Chaperones/metabolism , Nuclear Pore Complex Proteins/metabolism , Simian Acquired Immunodeficiency Syndrome/virology , Zoonoses/virology , Africa , Amino Acid Sequence , Animals , HIV Infections/metabolism , HIV Infections/transmission , HIV-1/pathogenicity , Host Specificity , Humans , Molecular Chaperones/genetics , Nuclear Pore Complex Proteins/genetics , Phylogeny , Primates , Sequence Homology , Simian Acquired Immunodeficiency Syndrome/metabolism , Simian Acquired Immunodeficiency Syndrome/transmission , Simian Immunodeficiency Virus/pathogenicity , Species Specificity , Virus Replication , Zoonoses/metabolism , Zoonoses/transmission
3.
J Virol ; 90(6): 3056-64, 2015 Dec 30.
Article in English | MEDLINE | ID: mdl-26719253

ABSTRACT

UNLABELLED: MxB restricts HIV-1 infection by directly interacting with the HIV-1 core, which is made of viral capsid; however, the contribution of MxB to the HIV-1 restriction observed in alpha interferon (IFN-α)-treated human cells is unknown. To understand this contribution, we used HIV-1 bearing the G208R capsid mutant (HIV-1-G208R), which overcomes the restriction imposed by cells expressing MxB. Here we showed that the reason why MxB does not block HIV-1-G208R is that MxB does not interact with HIV-1 cores bearing the mutation G208R. To understand whether MxB contributes to the HIV-1 restriction imposed by IFN-α-treated human cells, we challenged IFN-α-treated cells with HIV-G208R and found that MxB does not contribute to the restriction imposed by IFN-α-treated cells. To more directly test the contribution of MxB, we challenged IFN-α-treated human cells that are knocked out for the expression of MxB with HIV-1. These experiments suggested that MxB does not contribute to the HIV-1 restriction observed in IFN-α-treated human cells. IMPORTANCE: MxB is a restriction factor that blocks HIV-1 infection in human cells. Although it has been postulated that MxB is the factor that blocks HIV-1 infection in IFN-α-treated cells, this is a hard concept to grasp due to the great number of genes that are induced by IFN-α in cells from the immune system. The work presented here elegantly demonstrates that MxB has minimal or no contribution to the ability of IFN-α-treated human cells to block HIV-1 infection. Furthermore, this work suggests the presence of novel restriction factors in IFN-α-treated human cells that block HIV-1 infection.


Subject(s)
HIV-1/immunology , Interferon-alpha/metabolism , Myxovirus Resistance Proteins/metabolism , Cell Line , Gene Knockout Techniques , Humans , Myxovirus Resistance Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...